Clinical Trials Logo

Toxicity Due to Radiotherapy clinical trials

View clinical trials related to Toxicity Due to Radiotherapy.

Filter by:

NCT ID: NCT02079272 Withdrawn - Breast Cancer Clinical Trials

REBECCA Study (RadiothErapy for BrEast Cancer and CArdiotoxicity)

REBECCA
Start date: November 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether a new technique of radiotherapy for breast cancer (helical tomotherapy) can induce cardiac toxicity that would be detected in the first two years after treatment. Screening of subclinical cardiac lesions with non-invasive cardiac imaging techniques combined with measures of circulating biomarkers of cardiac tissue lesions and coronary lesions would allow assessing radiation-induced cardiac toxicity at an early stage.

NCT ID: NCT01999933 Recruiting - Cervical Cancer Clinical Trials

Evaluation of Postoperative Radiotherapy and Concurrent Chemotherapy Effectiveness in Cervical Cancer

Start date: November 2013
Phase: Phase 2/Phase 3
Study type: Interventional

The present study is a randomized, control, phase II/III study of early stage (FIGO Ia2-IIb) cervical cancer after radical hysterectomy in Northwest China treated with radiotherapy or concurrent chemoradiotherapy based on the surgical-pathological risk factors. All the patients received whole pelvis radiation and were divided into three groups according to adjuvant chemotherapy: concurrent chemotherapy with cisplatin weekly (40mg/m2) , concurrent chemotherapy with docetaxel plus cisplatin tri-weekly (75mg/m2), or concurrent and adjuvant chemotherapy with docetaxel plus cisplatin tri-weekly (75mg/m2). The effectiveness, and side effects will be evaluated according to Standard WHO response criteria, and NCI common toxicity criteria for adverse events(NCI-CTC-AE) V3.0.

NCT ID: NCT01596868 Completed - Clinical trials for Toxicity Due to Radiotherapy

GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China

Start date: May 2012
Phase: Phase 2
Study type: Interventional

The present study is a randomized, control, phase II study of locally advanced nasopharyngeal carcinoma (NPC) in Northwest China treated with Gemcitabine plus cisplatin regimen (GP) or Docetaxel plus cisplatin regimen (TP) induction chemotherapy followed by concurrent chemoradiotherapy. The population consists of stage III-IVb nasopharyngeal carcinoma (NPC). The effectiveness, side effects and quality of life will be evaluated according to Standard WHO response criteria, NCI-CTC AE V3.0 and EORTC QLQ-C30 and H&N35 questionnaire.